Stocktoria

Savara Inc SVRA

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2001-06-25 · LEI

Savara Inc financials (annual)

Revenue
$400000 $0 $0 $257000 2016201720182019202020212022202320242025
Net income
-$10.9M -$29.8M -$61.5M -$78.2M -$49.6M -$43.0M -$38.1M -$54.7M -$95.9M -$118.8M 2016201720182019202020212022202320242025
Free cash flow
-$8.4M -$28.7M -$39.4M -$45.3M -$39.9M -$40.1M -$34.6M -$51.4M -$89.1M -$101.1M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$257,000$0$0$400,000
SG&A expense$9.3M
Operating income-$123.5M-$103.2M-$60.0M-$38.8M-$41.5M-$49.3M-$79.0M-$70.0M-$30.0M-$10.9M
Interest expense$1.2M$452,000
Income tax$0$9,000-$7.1M-$3.6M-$357,000
Net income-$118.8M-$95.9M-$54.7M-$38.1M-$43.0M-$49.6M-$78.2M-$61.5M-$29.8M-$10.9M
EPS (diluted)$-0.53$-0.48$-0.33$-0.25$-0.32
Operating cash flow-$101.0M-$89.1M-$51.1M-$34.6M-$40.1M-$39.8M-$45.1M-$39.3M-$28.2M-$8.4M
Free cash flow-$101.1M-$89.1M-$51.4M-$34.6M-$40.1M-$39.9M-$45.3M-$39.4M-$28.7M-$8.4M
Cash & equivalents$33.2M$15.1M$26.6M$52.1M$34.0M$22.9M$49.8M$24.3M$22.1M$13.4M
Total assets$253.4M$212.9M$177.6M$139.8M$176.6M$97.7M$136.2M$152.3M$159.6M$28.9M
Total liabilities$50.3M$41.4M$37.2M$32.0M$32.1M$33.4M$34.5M$44.1M$40.3M$20.9M
Shareholders' equity$203.1M$171.4M$140.4M$107.8M$144.5M$64.4M$101.7M$108.2M$119.3M-$35.9M

Growth · year-over-year · Revenue CAGR -13.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-100.0%+640.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.